Akorn's diltiazem hydrochloride injection approved

By Elaine Rigoli

Tampa, Fla., July 28 - Akorn, Inc. said Friday that it received a second abbreviated New Drug Application approval for diltiazem hydrochloride injection, 5 mg/mL in 5 and 10 mL vials.

The company said this is the eighth product approval this year.

"Diltiazem is used to treat high blood pressure and to control chest pain (angina). Akorn expects to launch Diltiazem in the fourth quarter," president and chief executive officer Arthur S. Przybyl said in a news release.

Akorn manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Ill., and Somerset, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.